About The Study
Researchers in the FORWARD clinical trials want to find out if a study drug, called IMVT-1402, could potentially help people with Graves’ disease, as well as examine how safely it interacts with the body. The study treatment is designed to work differently from antithyroid drugs, by targeting the underlying cause of Graves’ disease. Participation in this clinical study may help researchers understand the effects of IMVT-1402 on people with Graves’ disease.
What Are The Benefits?
While there is no guarantee that you will benefit from receiving the study treatment, the information that doctors and researchers learn in this study may help improve what they know about treatments for adult patients with Graves’ disease, and may potentially help other people who are living with Graves’ disease in the future.
What Is Being Tested?
The main purpose of this clinical trial is to explore whether an investigational treatment (IMVT-1402) can address the underlying cause of Graves’ disease, and potentially normalize thyroid hormone levels. Since Graves’ disease (GD) is an autoimmune disease caused by antibodies, a possible disease-modifying approach researchers are examining is to target a receptor that may lead to antibody reduction. Read our FAQs to learn more about this study, and what to expect as a participant.
From the Community…
Clinical Trials Make A Difference
When you participate in a clinical study, you provide valuable information that could eventually lead to a better treatment and—with the right breakthrough—to better outcomes. Take our brief survey to see if you are a good fit. There is no obligation.
Participate In Innovation
Shape The Future
Help Others
Still Have Questions?
Contact us anytime at help@clinicalenrollment.com.